Utilizing pleiotropic cardio- and nephroprotective effects of SGLT-2-i and GLP-1-RA

Type 2 diabetes is currently understood to be a multisystemic disease, with the prognosis being significantly influenced by cardiac and renal pathology. An early, multimodal therapeutic approach that goes beyond pure blood glucose control is therefore important. There is now empirical evidence that SGLT-2 inhibitors and GLP-1 receptor agonists offer cardio- and nephroprotective benefits, and recent studies have shown that synergistic effects can be achieved through their combined use.